DOSAGE INDEX / SINGLE
Adipotide
Research, reported schedules and supply planning.
Review Adipotide vascular-targeting research, monkey fat-loss findings, kidney injury and the terminated human trial without inventing its outcomes.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 250–1,000 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 4–8 weeks
- Route / research model
- Subcutaneous
The source relies on preclinical work and discusses kidney toxicity. This is not an established human protocol.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Adipotide is an experimental peptidomimetic studied for targeting the blood vessels that support white adipose tissue. Its preclinical record includes weight-loss findings in obese monkeys and an important kidney-toxicity signal. The human trial record checked for this profile is terminated and has no results posted. Those facts do not support a consumer fat-loss protocol. [1] [2]
- Barnhart and colleagues reported reduced body weight and white adipose tissue, with improved insulin-resistance measurements, in obese monkeys. Imaging and body-composition methods supplemented scale weight. The same research identified renal proximal-tubule dysfunction and injury. Some changes improved during recovery, but reversibility was not complete at every dose and observation point. [1]
- Kidney injury is reported in the cited primate work. The uncertainty is how those observations translate to human risk, not whether the animal safety signal can be ignored. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Primate study
- human trial record
- Science Translational Medicine (PubMed)Further reading · Listed in reference bibliography.
- MD Anderson Cancer CenterFurther reading · Listed in reference bibliography.
- Cardiovascular Diabetology (PMC)Further reading · Listed in reference bibliography.
- BC Open Textbook ProjectFurther reading · Listed in reference bibliography.
- Immunize.org (IAC)General guidance · Listed in reference bibliography.
- Los Angeles TimesFurther reading · Listed in reference bibliography.
- ScienceDailyFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.